
TFW

Sterne Kessler Goldstein Fox
ATTORNEYS AT LAW



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Horner
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr
Michael V. Messinger
Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Donald R. Banowit
Peter A. Jackman
Jeffrey S. Weaver
Brian J. Del Buono
Edward W. Yee
Vincent L. Capuano
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Rae Lynn P. Guest
Daniel A. Klein

Jason D. Eisenberg
Michael D. Specht
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longsworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Matthew E. Kelley
Michelle K. Holoubek•
Marsha A. Rose•

Christopher J. Walsh
W. Blake Coblentz•
James J. Pohl*
Young Tang
John T. Haran•
Mark W. Rygiel

Registered Patent Agents•
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse

Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
•Admitted only in Virginia
•Practice Limited to Federal Agencies

May 11, 2006

WRITER'S DIRECT NUMBER:
(202) 772-8641
INTERNET ADDRESS:
HCARLSON@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1649

Attn: Mail Stop Issue Fee

Re: Allowed Utility Patent Application
Application No. 10/067,800; Filed: February 8, 2002
For: **Human G-Protein Chemokine Receptor (CCR5) HDGNR10**
Inventors: Roschke *et al.*
Our Ref: 1488.115000I/EKS/HCC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Statement of Substance of Interview Under 37 C.F.R. § 1.133, As Required by the Examiner; and

2. One return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Helene C. Carlson
Agent for Applicants
Registration No. 47,473

EKS/HCC/eaf
Enclosures

531754v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:
Roschke *et al.*
Appl. No.: 10/067,800
Filed: February 8, 2002
For: **Human G-Protein Chemokine Receptor (CCR5) HDGNR10**

Confirmation No.: 8493
Art Unit: 1649
Examiner: Turner, Sharon L.
Atty. Docket: 1488.1150000I

Statement of Substance of Interview Under 37 C.F.R. § 1.133, As Required by the Examiner

Attn: Mail Stop Issue Fee

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Further to the Interview Summary faxed on April 12, 2006, Applicants believe that an Applicants' Statement of Substance of Interview is not required because the Interview was solely of a procedural nature and involved no substantive matters, i.e., it did not involve a discussion of the merits of the application, nor did it require a reconsideration of the claims. However, the Interview Summary states that Applicants must file a statement of the substance of the interview within a stated non-extendable period. Therefore, Applicants' submit the following statement in accordance with 37 C.F.R. § 1.133 and MPEP § 713.04, solely as a formality.

On April 11, 2006, Applicants' representative called Examiner Sharon Turner to request consideration of Information Disclosure Statement (IDS) Document AK3, filed February 15, 2005, and the IDS documents filed on February 1, 2006 in the above-captioned application. The Examiner kindly agreed to consider these IDS documents

and to forward to the undersigned representative initialed copies of the IDS forms by facsimile.

In addition, the Examiner discussed the request for information made by the printer, and Applicants' representative authorized an Examiner's Amendment in consideration of the printer's request.

Applicants also provide the following information concerning the interview:

(A) Exhibits shown or demonstrations conducted: None.

(B) Claims discussed: None.

(C) Prior art discussed: None.

(D) Amendments of a substantive nature: None.

(E) Principal arguments of Applicants: None

(F) Other pertinent matter: None.

(G) Outcome: See infra, paragraph spanning pages 1 and 2; see infra, page 2, first paragraph.

Applicants' believe that the filing of this paper should ***not*** be counted against any patent term adjustment to which this application may be entitled, as the paper was necessitated by the Examiner's Interview Summary.

The Examiner is invited to contact the Applicants' undersigned representative at the number provided with any inquiries regarding this Statement.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: May 11, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

531765v1